Literature DB >> 25877914

Is peritoneal dialysis still an equal option? Results of the Berlin pediatric nocturnal dialysis program.

Julia Thumfart1, Tanja Hilliger, Christina Stiny, Steffen Wagner, Uwe Querfeld, Dominik Müller.   

Abstract

BACKGROUND: Peritoneal dialysis (PD) or conventional hemodialysis (HD) are considered to be equally efficient dialysis methods in children and adolescents. The aim of our study was to analyze whether an intensified, nocturnal HD program (NHD) is superior to PD in an adolescent cohort.
METHODS: Thirteen patients were prospectively enrolled in a NHD program. We measured uremia-associated parameters, parameters for nutrition, medication and blood pressure and analyzed the data. These data were compared to those of 13 PD controls, matched for gender, age and weight at the beginning the respective dialysis program and after 6 months of treatment.
RESULTS: Serum phosphate levels decreased significantly in the NHD group and remained unchanged in the PD group. Arterial blood pressure in the NHD was significantly lower despite the reduction of antihypertensive treatment, whereas blood pressure levels remained unchanged in the PD controls. Preexisting left ventricular hypertrophy resolved and albumin levels improved with NHD. Dietary restrictions could be lifted for those on NHD, whereas they remained in place for the patients on PD treatment. Residual diuresis remained unchanged after 6 months of either NHD or PD. NHD patients experienced fewer days of hospitalization than the PD controls.
CONCLUSIONS: Based on our results, NHD results in significantly improved parameters of uremia and nutrition. If individually and logistically possible, NHD should be the treatment modality of preference for older children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25877914     DOI: 10.1007/s00467-015-3043-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  28 in total

1.  Intensive hemodialysis associates with improved survival compared with conventional hemodialysis.

Authors:  Gihad E Nesrallah; Robert M Lindsay; Meaghan S Cuerden; Amit X Garg; Friedrich Port; Peter C Austin; Louise M Moist; Andreas Pierratos; Christopher T Chan; Deborah Zimmerman; Robert S Lockridge; Cécile Couchoud; Charles Chazot; Norma Ofsthun; Adeera Levin; Michael Copland; Mark Courtney; Andrew Steele; Philip A McFarlane; Denis F Geary; Robert P Pauly; Paul Komenda; Rita S Suri
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

Review 2.  Cardiovascular disease in children with chronic kidney disease.

Authors:  Mark M Mitsnefes
Journal:  J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 10.121

3.  Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children.

Authors:  Claus P Schmitt; Börje Haraldsson; Rouven Doetschmann; Mirjam Zimmering; Christine Greiner; Michael Böswald; Günter Klaus; Jutta Passlick-Deetjen; Franz Schaefer
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

4.  The assessment of body water and fatness from infancy to adulthood.

Authors:  E D Mellits; D B Cheek
Journal:  Monogr Soc Res Child Dev       Date:  1970-10

Review 5.  Phosphate is a vascular toxin.

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-11-17       Impact factor: 3.714

Review 6.  Optimizing peritoneal dialysis prescription for volume control: the importance of varying dwell time and dwell volume.

Authors:  Michel Fischbach; Ariane Zaloszyc; Betti Schaefer; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2013-08-02       Impact factor: 3.714

7.  Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification.

Authors:  Rukshana C Shroff; Rosamund McNair; Jeremy N Skepper; Nichola Figg; Leon J Schurgers; John Deanfield; Lesley Rees; Catherine M Shanahan
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

8.  Effect of membrane permeability on survival of hemodialysis patients.

Authors:  Francesco Locatelli; Alejandro Martin-Malo; Thierry Hannedouche; Alfredo Loureiro; Menelaos Papadimitriou; Volker Wizemann; Stefan H Jacobson; Stanislaw Czekalski; Claudio Ronco; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

9.  Effect of the dialysis fluid buffer on peritoneal membrane function in children.

Authors:  Claus Peter Schmitt; Barbara Nau; Gita Gemulla; Klaus E Bonzel; Tuula Hölttä; Sara Testa; Michel Fischbach; Ulrike John; Markus J Kemper; Anja Sander; Klaus Arbeiter; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 8.237

10.  Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis.

Authors:  Rukshana C Shroff; Rosamund McNair; Nichola Figg; Jeremy N Skepper; Leon Schurgers; Ashmeet Gupta; Melanie Hiorns; Ann E Donald; John Deanfield; Lesley Rees; Catherine M Shanahan
Journal:  Circulation       Date:  2008-10-06       Impact factor: 29.690

View more
  4 in total

Review 1.  Hypertension in Pediatric Dialysis Patients: Etiology, Evaluation, and Management.

Authors:  Raj Munshi; Joseph T Flynn
Journal:  Curr Hypertens Rep       Date:  2018-06-08       Impact factor: 5.369

Review 2.  Extrarenal effects of FGF23.

Authors:  Dieter Haffner; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2016-10-04       Impact factor: 3.714

Review 3.  Blood pressure management in children on dialysis.

Authors:  F Paglialonga; S Consolo; A Edefonti; G Montini
Journal:  Pediatr Nephrol       Date:  2017-06-09       Impact factor: 3.714

4.  Glomerular disease patients have higher odds not to reach quality targets in chronic dialysis compared with CAKUT patients: analyses from a nationwide German paediatric dialysis registry.

Authors:  Katrin Lübbe; Eva Nüsken; Katherine Rascher; Gero von Gersdorff; Heyke Cramer; Christina Samel; Claudia Barth; Dieter Bach; Lutz T Weber; Jörg Dötsch
Journal:  Pediatr Nephrol       Date:  2019-03-06       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.